Earnings Play: Johnson & Johnson

On Thursday Johnson & Johnson is expected to release 2Q earnings.

Uptrend 1

On Thursday, Johnson & Johnson (JNJ) is expected to report second quarter EPS of $1.50 compared to $2.58 a year ago on revenue of approximately $17.6B vs. $20.6B last year. Johnson & Johnson is the world's largest and most diverse healthcare products company and on July 14th, Janssen Pharmaceutical, a subsidiary of the company, received approval from the U.S. Food and Drug Administration (FDA) for Tremfya, a treatment for adult patients with active psoriatic arthritis, according to Bloomberg.    

From a technical point of view, on a daily chart, Johnson & Johnson's stock price has just broken out to the upside of a descending channel pattern that began to form in late-April after the company reached a record high of $157.00. The RSI is showing upward momentum after breaking to the upside of a bearish trend line. Price appears to be headed to retest the 153.00 resistance level and since we are still in a bull market, the bias on stocks remains bullish. If price can reach $153.00 it would clear a path towards retesting the all time high of $157.00. If price can not hold above the upper trend line of the descending channel pattern we could see price fall back to the $143.00 support level. If price re-enters the descending channel it may continue to decline down to $137.00.         

Source: GAIN Capital, TradingView

More from Earnings


This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

GAIN Capital Singapore Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the GAIN Capital group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), GAIN Capital Singapore Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact GAIN Capital Singapore Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither GAIN Capital Singapore Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

GAIN Capital Singapore Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit cityindex.com.sg for the complete Risk Disclosure Statement.

Important Notice:

Cryptocurrencies are not legal tender currency and trading of derivatives on Cryptocurrencies are currently not covered under any regulatory regime in Singapore. Consequently, investors should be aware they do not have protection under the Securities and Futures Act (Cap. 289). Please ensure that you are fully aware of the risks.